ascopubs.org1d
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...
ascopubs.org1d
The role of stereotactic radiotherapy in brain metastases from gastrointestinal cancer.
A phase 1 trial of folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) in microsatellite stable metastatic colorectal cancer. Phase I/II trial of encorafenib, ...
ascopubs.org2d
The prevalence and prognostic significance of KRAS G12C mutation in metastatic colorectal cancer.
Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...
ascopubs.org2d
Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
ascopubs.org2d
Correlates of Cetuximab Efficacy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Previously Treated With Immunotherapy
Optimizing Radiotherapy Timing for Nasopharyngeal Carcinoma: The Impact of Radiation Scheduling on Survival We performed a single-institution retrospective analysis of patients with R/M HNSCC treated ...
ascopubs.org3d
Prognosis of signet ring cell (SRC) gastric carcinoma (GC) compared with other histological subtypes.
Prognostic impact of postoperative complications after neoadjuvant therapy followed by esophagectomy for esophageal cancer: An exploratory analysis of phase III trial JCOG1109.
ascopubs.org3d
Real-world evidence on genomic profiles and survival outcomes in patients with HER2-positive metastatic colorectal cancer.
Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data. This is an ASCO Meeting ...
ascopubs.org3d
Adjuvant chemotherapy or chemo-radiation in gallbladder cancer: A phase III randomized controlled study (ACCELERATE trial).
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling. Nivolumab (NIVO) plus ...
ascopubs.org3d
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Abbreviations: CR, complete response; ECOG, Eastern Cooperative Oncology Group; IFS, infantile fibrosarcoma; NOS, not otherwise specified; PD, progressive disease; PR ...
ascopubs.org3d
Neoadjuvant therapy in T3 and T4 colon cancer: Is there a promising future?
Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study. Updated analysis of ...
ascopubs.org3d
Anlotinib plus benmelstobart as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II clinical trial (ALTER-E005).
Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109. This is an ASCO ...
ascopubs.org3d
Real-world treatment patterns among U.S. adults with unresectable hepatocellular carcinoma (uHCC) eligible for locoregional therapy (LRT).
Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC). Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations ...